Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
Madlen Jentzsch, Juliane Grimm, Marius Bill, Dominic Brauer, Donata Backhaus, Julia Schulz, Karoline Goldmann, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind
Abstract
Acute myeloid leukemia (AML) presents highly heterogeneous, calling for individualized treatment approaches. Allogeneic hematopoietic stem cell transplantation (HSCT) offers the consolidation treatment with the highest chance of sustained remission for most AML patients 1 . In patients refractory to induction therapy or suffering early relapse, allogeneic HSCT may be performed as a salvage therapy despite the detection of active disease 2 .
Topics & Concepts
MedicineInternal medicineHematopoietic stem cell transplantationMinimal residual diseaseTransplantationOncologyDiseaseLeukemiaAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationHistone Deacetylase Inhibitors Research